Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Abstract c-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …
Progression and metastasis of lung cancer
HH Popper - Cancer and Metastasis Reviews, 2016 - Springer
Metastasis in lung cancer is a multifaceted process. In this review, we will dissect the
process in several isolated steps such as angiogenesis, hypoxia, circulation, and …
process in several isolated steps such as angiogenesis, hypoxia, circulation, and …
Current approaches to the treatment of metastatic brain tumours
Metastatic tumours involving the brain overshadow primary brain neoplasms in frequency
and are an important complication in the overall management of many cancers. Importantly …
and are an important complication in the overall management of many cancers. Importantly …
Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer
Purpose: MET exon 14 splice site alterations that cause exon skipping at the mRNA level
(MET ex14) are actionable oncogenic drivers amenable to therapy with MET tyrosine kinase …
(MET ex14) are actionable oncogenic drivers amenable to therapy with MET tyrosine kinase …
Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
T Iuchi, M Shingyoji, M Itakura, S Yokoi… - International journal of …, 2015 - Springer
Background The brain is a frequent site of metastases from non-small-cell lung cancer
(NSCLC). We analyzed the frequency of brain metastases (BMs) from NSCLC in the era of …
(NSCLC). We analyzed the frequency of brain metastases (BMs) from NSCLC in the era of …
[HTML][HTML] Biological insights in non-small cell lung cancer
R Rosell, A Jain, J Codony-Servat… - Cancer Biology & …, 2023 - ncbi.nlm.nih.gov
Lung oncogenesis relies on intracellular cysteine to overcome oxidative stress. Several
tumor types, including non-small cell lung cancer (NSCLC), upregulate the system x c …
tumor types, including non-small cell lung cancer (NSCLC), upregulate the system x c …
The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma
SN Steinway, H Dang, H You, CB Rountree, W Ding - PLoS One, 2015 - journals.plos.org
Background c-Met, a high-affinity receptor for Hepatocyte Growth Factor (HGF), plays a
critical role in tumor growth, invasion, and metastasis. Hepatocellular carcinoma (HCC) …
critical role in tumor growth, invasion, and metastasis. Hepatocellular carcinoma (HCC) …
The role of EGF‐EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment
P Huang, X Xu, L Wang, B Zhu… - Journal of cellular and …, 2014 - Wiley Online Library
Epidermal growth factor (EGF) and their receptor (EGFR) play an important role in the
development of cancer proliferation, and metastasis, although the mechanism remains …
development of cancer proliferation, and metastasis, although the mechanism remains …
[HTML][HTML] BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation
EGFR TKI therapy has become a first-line regimen for non-small cell lung cancer (NSCLC)
patients with EGRF mutations. However, there are two big challenges against effective …
patients with EGRF mutations. However, there are two big challenges against effective …
[HTML][HTML] Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: a review of the literature
Brain metastasis (BM) is the most common event in patients with lung cancer. Despite
multimodal treatments and advances in systemic therapies, development of BM remains one …
multimodal treatments and advances in systemic therapies, development of BM remains one …